Wegovy-maker Novo Nordisk to cut around 9,000 jobs
On Monday, April 28, 2025, Vermont, Waterbury, wegovy injection items held in Vermont.
Shelby Knowles | Bloomberg | Getty Images
On Wednesday, the Danish Pharmaceutical Giant Novo Nordisk announced that it plans to reduce approximately 9,000 roles or about 11.5% of the global labor force.
“Novo Nordisk today announced a company -wide transformation to simplify the organization, improve decision -making, and direct resources to the growth opportunities in diabetes and obesity,” the company produced weight loss medications. ” He said.
“As part of the transformation, Novo Nordisk plans to reduce the global labor force about 9,000 of the 78,400 positions in the company and is expected about 5,000 discounts in Denmark.”
The company said that the reduction of the number of personnel will be exposed to a one -time cost of 8 billion Danish crowns ($ 1.26 billion).
As a result of a one -time costs, the company said that the second quarter of August is expected to be 4 to 10% from 10% to 16% to 16% to 16% in August.
Revision, CEO and President Maziar Mike Dustdar’s Lars Fruergaard Jørgensen’s surprise practice, indicates the first major movement to take renuncies in the Pharma giant.
Novo Nordisk is once the first carrier in weight loss drugs, especially in the US region, to protect the market share in the midst of increasing competition from rival Eli Lilly and cheaper compound weight loss drugs in the US region.
“Our markets are developing because they become more competitive and consumer, especially in obesity.
drilled. Our company should also develop. This means to instill an increasing culture of performance, to distribute our resources more effectively, and to give priority behind our therapy areas that will have the most impact of investment. “He said.
Dousdar, who confirmed his appointment during an investor in July, said that he had undertaken the role with “urgency” and three basic priorities. Among them included Novo’s leadership in the treatment of diabetes and obesity, encouraging a high -performance culture, and reorganizing the company’s cost base and increasing productivity.
This is an developing story and will be updated soon.
